DEPDC1在子宫内膜癌中表达上调

doi:10.16352/j.issn.1001-6325.2023.09.1399

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (9): 1399-1407.doi: 10.16352/j.issn.1001-6325.2023.09.1399

DEPDC1在子宫内膜癌中表达上调

杨婷婷, 黄洁, 郭建新, 韩健^*

陆军军医大学陆军特色医学中心妇产科,重庆 400042

收稿日期:2023-04-18 修回日期:2023-07-11 出版日期:2023-09-05 发布日期:2023-09-01
通讯作者: ^*hj.obgyn@outlook.com

DEPDC1 is up-regulated in uterine corpus endometrial cancer

YANG Tingting, HUANG Jie, GUO Jianxin, HAN Jian^*

Department of Obstetrics and Gynaecology, Army Medical Center of PLA (Daping Hospital), Army Medical University, Chongqing 400042, China

Received:2023-04-18 Revised:2023-07-11 Online:2023-09-05 Published:2023-09-01
Contact: ^*hj.obgyn@outlook.com

摘要/Abstract

摘要： 目的观察DEP结构域蛋白1(DEPDC1)在子宫内膜癌(UCEC)中的表达及作用。方法利用GEO和TCGA等公共数据库分析DEPDC1 mRNA在UCEC中的表达情况,以及其与临床病理参数及预后的相关性;利用组织芯片、免疫印迹和实时定量PCR检测DEPDC1在UCEC组织和细胞系中的表达;利用平板集落、CCK8法和裸鼠成瘤等实验检测DEPDC1对UCEC细胞系增殖的影响。结果 DEPDC1 mRNA在UCEC中表达上调(P＜0.001),其表达与UCEC临床分期(P＜0.001)、组织分化程度(P＜0.05)及病理类型(P＜0.001)等临床病理参数显著相关;相较于DEPDC1 mRNA低表达的患者,高表达的患者疾病特异生存期(DSS)和无进展期(PFI)显著降低(P＜0.01);DEPDC1在UCEC组织和细胞系中高表达,敲降DEPDC1后,UCEC细胞系的集落形成减少、细胞率降低(P＜0.01)和体内成瘤能力下降(P＜0.05)。结论 DEPDC1在UCEC中表达上调,参与UCEC的恶性进展及影响患者预后,并在UCEC细胞系增殖中发挥重要调控作用。

关键词: 子宫内膜癌, DEP结构域蛋白1(DEPDC1), 增殖

Abstract: Objective To explore the expression and function of DEP domain containing 1 (DEPDC1) in uterine corpus endometrial cancer(UCEC). Methods The Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases were used to analyze the expression of DEPDC1 mRNA in normal endometrial tissues and UCEC tissues, the relationship with patient clinicopathological parameters and prognosis. Immuno-histochemistry (IHC), Western blot and RT-qPCR were used to detect the expression of DEPDC1 in UCEC cell lines and tissue. The CCK-8 assay, colony formation assay, and tumor xenograft were used to investigate the effect of DEPDC1 on cancer proliferation. Results DEPDC1 mRNA was up-regulated in UCEC (P＜0.001) and was correlated with the clinical stages (P＜0.001), tissue differentiation (P＜0.05) and histological type(P＜0.001) of UCEC. Compared with the DEPDC1 mRNA low expression patients, the patients with high expression of DEPDC1 showed lower disease-specific survival(DSS) and progress-free interval (PFI) (P＜0.01). The IHC, Western blot, and RT-qPCR showed that DEPDC1 was up-regulated both in UCEC tissue and cell lines. Down regulation of DEPDC1 inhibited the colony formation, invasion and tumor sphere formation, cell proliferation rate, and tumourigenesis in vivo. Conclusions DEPDC1 is up-regulated in UCEC that is correlated with the malignant progression and poor prognosis of UCEC.

Key words: uterine corpus endometrial cancer, DEP domain containing 1 (DEPDC1), proliferation

中图分类号:

R737.33

杨婷婷, 黄洁, 郭建新, 韩健. DEPDC1在子宫内膜癌中表达上调[J]. 基础医学与临床, 2023, 43(9): 1399-1407.

YANG Tingting, HUANG Jie, GUO Jianxin, HAN Jian. DEPDC1 is up-regulated in uterine corpus endometrial cancer[J]. Basic & Clinical Medicine, 2023, 43(9): 1399-1407.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2023.09.1399

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2023/V43/I9/1399

参考文献

[1]Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66: 115-132.
[2]Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67: 7-30.
[3]Crosbie EJ, Kitson SJ, Mcalpine JN, et al. Endometrial cancer[J]. Lancet, 2022, 399: 1412-1428.
[4]Legge F, Restaino S, Leone L, et al. Clinical outcome of recurrent endometrial cancer: analysis of post-relapse survival by pattern of recurrence and secondary treatment[J]. Int J Gynecol Cancer, 2020, 30: 193-200.
[5]Matei D, Filiaci V, Randall ME, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer[J]. N Engl J Med, 2019, 380: 2317-2326.
[6]Kanehira M, Harada Y, Takata R, et al. Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis[J]. Oncogene, 2007, 26: 6448-6455.
[7]Feng X, Zhang C, Zhu L, et al. DEPDC1 is required for cell cycle progression and motility in nasopharyngeal carcinoma[J]. Oncotarget,2017, 8: 63605-63619.
[8]Shen L, Li H, Liu R, et al. DEPDC1 as a crucial factor in the progression of human osteosarcoma[J]. Cancer Med, 2023, 12: 5798-5808.
[9]Qu D, Cui F, Lu D, et al. DEP domain containing 1 predicts prognosis of hepatocellular carcinoma patients and regulates tumor proliferation and metastasis[J]. Cancer Sci,2019, 110: 157-165.
[10]Wang Q, Jiang S, Liu J, et al. DEP Domain containing 1 promotes proliferation, invasion, and epithelial-mesenchymal transition in colorectal cancer by enhancing expression of suppressor of zest 12[J]. Cancer Biother Radiopharm, 2021, 36: 36-44.
[11]贺晶,李艳,王延峰,等. FABP4表达上调促进人子宫内膜癌细胞系HEC-1-A增殖和迁移[J]. 基础医学与临床, 2022, 42: 1356-1361.
[12]王晴晴,李爱丽,黄国锦. 含DEP结构域的蛋白质1在癌症发生发展中的作用[J]. 广西医学, 2016, 38: 1740-1743.

[1]	潘闪, 林铿强, 陈树兴. 培美曲塞抑制人肺腺癌细胞系A549增殖[J]. 基础医学与临床, 2023, 43(9): 1359-1363.
[2]	朱锋, 钟粤, 邓义江, 刘文值, 边疆. 右美托咪定通过上调PPAR-γ改善神经病理性疼痛模型大鼠的痛觉敏化[J]. 基础医学与临床, 2023, 43(9): 1369-1374.
[3]	梁辉勇, 韦秋慧, 丁亚, 彭小青, 姚静, 苏齐鉴. 虫草素抑制TNF-α诱导的人角质形成细胞系HaCaT增殖[J]. 基础医学与临床, 2023, 43(9): 1390-1393.
[4]	黄洁, 李润博, 郭建新, 韩健. DDX5和DDX17在卵巢癌组织中的表达及对人卵巢癌细胞系SKOV3增殖和耐药的影响[J]. 基础医学与临床, 2023, 43(8): 1247-1253.
[5]	张培波, 李义. 沙棘总黄酮抑制膀胱癌细胞系T24增殖[J]. 基础医学与临床, 2023, 43(7): 1122-1126.
[6]	唐一君, 王文龙, 李江丽, 杨欢, 孙静. LncRNA RP11-686D22.10与乳腺癌患者生存期相关并影响乳腺癌细胞系的增殖和侵袭[J]. 基础医学与临床, 2023, 43(7): 1023-1029.
[7]	金晓霞, 陆晓云, 刘玉山, 梁李娜. SIRT2在膀胱尿路上皮癌中的表达、临床意义及其对癌细胞增殖、侵袭和迁移的影响[J]. 基础医学与临床, 2023, 43(7): 1090-1096.
[8]	曾燕坤, 洪小颖, 陈清林. 下调BECN1抑制人白血病细胞系THP-1增殖、侵袭和迁移[J]. 基础医学与临床, 2023, 43(7): 1104-1109.
[9]	苏靓誉, 张振西, 杜文静. TPX2的表达对胰腺癌预后的影响[J]. 基础医学与临床, 2023, 43(6): 875-881.
[10]	侯孟杰, 赵娜, 黄富强, 王亚南, 刘芳铭. 载脂蛋白E通过降低高尔基体膜蛋白73表达抑制小鼠肝癌细胞系增殖[J]. 基础医学与临床, 2023, 43(5): 762-770.
[11]	刘月, 曹阳, 顾伟英, 商丽梅, 刘琰. 地西他滨联合三氧化二砷抑制急性髓系白血病细胞系增殖和促进凋亡[J]. 基础医学与临床, 2023, 43(4): 608-614.
[12]	王芳芳, 曹慧媛, 汪婧, 王宁, 黄国良. 上调miR-200c-5p的表达抑制人结直肠癌细胞系SW480增殖[J]. 基础医学与临床, 2023, 43(2): 241-245.
[13]	杨良权, 于淼, 姜茜, 张明慧, 杨海松. miR-504调控蛋白酶体激活因子抑制人乳腺癌细胞系MCF-7增殖及迁移[J]. 基础医学与临床, 2023, 43(1): 95-101.
[14]	贺晶, 李艳, 王延峰, 鲍慧. FABP4表达上调促进人子宫内膜癌细胞系HEC-1-A增殖和迁移[J]. 基础医学与临床, 2022, 42(9): 1356-1361.
[15]	张晓雷, 刘静, 李朝萍. Circ_0032821参与索拉非尼抑制乳腺癌细胞系T47D增殖、迁移和侵袭[J]. 基础医学与临床, 2022, 42(9): 1350-1354.

DEPDC1在子宫内膜癌中表达上调

DEPDC1 is up-regulated in uterine corpus endometrial cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价